Table 4.
Network meta-analysis including KEYNOTE-355 patients assigned to gemcitabine/carboplatin.
| Overall survival | |||
|---|---|---|---|
| Gemcitabine + carboplatin | 1.25 (0.82, 1.91) | 0.91 (0.66, 1.26) | 1.14 (0.79, 1.63) |
| 0.80 (0.52, 1.22) | Nab-paclitaxel + carboplatin | 0.73 (0.50, 1.07) | 0.91 (0.52, 1.58) |
| 1.10 (0.79, 1.52) | 1.37 (0.94, 2.00) | Nab-paclitaxel + gemcitabine | 1.25 (0.77, 2.02) |
| 0.88 (0.62, 1.26) | 1.10 (0.63, 1.92) | 0.80 (0.50, 1.30) | Pembrolizumab + gemcitabine/carboplatin |
| Progression-free survival | |||
|---|---|---|---|
| Gemcitabine + carboplatin | 1.72 (1.10, 2.69) | 1.02 (0.77, 1.35) | 1.21 (0.84, 1.72) |
| 0.58 (0.37, 0.91) | Nab-paclitaxel + carboplatin | 0.59 (0.41, 0.86) | 0.70 (0.40, 1.24) |
| 0.98 (0.74, 1.30) | 1.69 (1.17, 2.46) | Nab-paclitaxel + gemcitabine | 1.18 (0.75, 1.86) |
| 0.83 (0.58, 1.18) | 1.43 (0.81, 2.53) | 0.84 (0.54, 1.33) | Pembrolizumab + gemcitabine/carboplatin |
Each cell represents the comparison (HR and 95% CrI) of the row treatment vs the column treatment. All bolded values are statistically meaningful at the 0.05 level. Overall survival: deviance information criterion: 5.25; deviance: 2.25. Progression-free survival: Deviance information criterion: 5.25; deviance: 2.25.
HR: Hazard ratio; CrI: Credible interval.